The COVID-19 pandemic has highlighted the importance of testing for diseases, with many individuals undergoing PCR or ELISA tests in recent years. However, these testing methods have limitations such as requiring large sample volumes, complex procedures, and potential exposure risks. In response to these challenges, a group of researchers has developed a new quantitative testing system called the “Express Biochecker,” which offers a simple, rapid, and cost-effective method for detecting the coronavirus N protein. This system, utilizing advanced microfluidic technology, is not limited to COVID-19 and is expected to be utilized for other viral illnesses like influenza and hepatitis in the future.
The novel immunoassay system of the “Express Biochecker” is based on Janus particles, named after the Roman god with two sides. One side is coated with a fluorescent dye, while the other side features magnetic particles and antibodies. These particles are designed to bind specifically to target antigens, such as viral proteins, and can be utilized with antibody-immobilized microfluidic devices for precise measurements. The versatility of this system allows for potential applications in detecting various disease markers, expanding possibilities for medical diagnostics.
Professor Hiroshi Yabu, the Principal Investigator and Deputy Director of the Open Innovation Center of Hydrogen Science for Green Transformation at Tohoku University’s Advanced Institute for Materials Research, highlights the potential of the system beyond viral detection. Professor Eiichi Kodama from the International Research Institute of Disaster Science at Tohoku University emphasizes that the system could also be adapted for measuring other biomarkers related to different conditions, paving the way for new advancements in medical diagnostics. The innovative nature of the “Express Biochecker” opens new avenues for disease detection and monitoring.
The research team’s findings on the “Express Biochecker” system were published in the journal Langmuir on August 15, 2024, shedding light on the groundbreaking advancements in disease testing technology. Professor Kentaro Totsu of the Micro System Integration Center, along with Haplo Pharma Inc., a company specializing in developing diagnostic devices for medical and healthcare applications, also played essential roles in the research project. With further exploration and development, the system holds promise for revolutionizing disease testing, offering a more efficient and effective approach to detecting various diseases beyond COVID-19.
The potential of the “Express Biochecker” system lies in its adaptability to detect a wide range of disease markers and biomarkers, allowing for a more comprehensive approach to medical diagnostics. By incorporating advanced microfluidic technology and Janus particles with fluorescent dye and magnetic properties, the system offers a highly precise and versatile testing method. As research progresses, the focus will be on expanding the system’s applications to include the detection of additional disease markers, contributing to improved healthcare and disease management strategies.
In conclusion, the development of the “Express Biochecker” system represents a significant milestone in disease testing technology, offering a simple, rapid, and cost-effective method for detecting various disease markers. With its potential applications beyond COVID-19 and adaptability to measure different biomarkers, the system holds great promise for advancing medical diagnostics. Collaborative efforts between researchers, industry partners, and healthcare professionals are essential in furthering the capabilities of this innovative testing system, ultimately benefiting individuals worldwide in disease detection and management.